Prolonged QT Interval in Cirrhosis: Twisting Time?

William Lee¹,², Bert Vandenberk¹,³, Satish R. Raj¹,⁴, and Samuel S. Lee⁵

¹Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²St Vincent’s Clinical School, University of New South Wales, Sydney, Australia, ³Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, ⁴Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, and ⁵Liver Unit, Snyder Institute for Chronic Disease, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Approximately 30% to 70% of patients with cirrhosis have QT interval prolongation. In patients without cirrhosis, QT prolongation is associated with an increased risk of ventricular arrhythmias, such as torsade de pointes (TdP). In cirrhotic patients, there is likely a significant association between the corrected QT (QTc) interval and the severity of liver disease, and possibly with increased mortality. We present a stepwise overview of the pathophysiology and management of acquired long QT syndrome in cirrhosis. The QT interval is mainly determined by ventricular repolarization. To compare the QT interval in time it should be corrected for heart rate (QTc), preferably by the Fridericia method. A QTc interval >450 ms in males and >470 ms in females is considered prolonged. The pathophysiological mechanism remains incompletely understood, but may include metabolic, autonomic or hormonal imbalances, cirrhotic heart failure and/or genetic predisposition. Additional external risk factors for QTc prolongation include medication (Iβ blockade and altered cytochrome P450 activity), bradycardia, electrolyte abnormalities, underlying cardiomyopathy and acute illness. In patients with cirrhosis, multiple hits and cardiac-hepatic interactions are often required to sufficiently erode the repolarization reserve before long QT syndrome and TdP can occur. While some risk factors are unavoidable, overall risk can be mitigated by electrocardiogram monitoring and avoiding drug interactions and electrolyte and acid-base disturbances. In cirrhotic patients with prolonged QTc interval, a joint effort by cardiologists and hepatologists may be useful and significantly improve the clinical course and outcome. (Gut Liver 2022;16:849-860)

Key Words: Acquired long QT syndrome; Torsade de pointes; Cirrhosis; Drug interaction; Ventricular repolarization

INTRODUCTION

The prevalence of electrocardiographic QT interval prolongation in patients with cirrhosis ranges between 30% and 70%. In fact, the seminal paper by Kowalski and Abelmann¹ that launched the modern era of cardio-hepato-

tology in 1953 already reported a prolonged QT interval in eight of the 22 subjects. Unfortunately, it was merely an incidental finding that was not further discussed, as the main point of the paper was the demonstration of hyperdynamic circulation in cirrhosis. This phenomenon then remained ignored until 1998, when Bernardi et al.⁵ performed a detailed study of QT prolongation in cirrhosis and found a significant correlation between the rate-corrected QT (QTc) interval and the Child-Pugh score, and that QTc prolongation may be associated with poor outcomes including mortality. Since then hundreds of studies of repolarization in cirrhosis have appeared. Despite these efforts, the underlying pathophysiology of QT prolongation in
cirrhosis is poorly understood. Proposed mechanisms such as bile salt accumulation, altered autonomic tone, shifts in gonadal hormone balance and cirrhotic cardiomyopathy have been suggested.

The QTc interval can easily be obtained from a 12-lead electrocardiogram (ECG). Hence, it is easily accessible as 12-lead ECGs are noninvasive, simple, inexpensive and routinely done in hospitalized and ambulatory patients to detect a long QT syndrome (LQTS). LQTS can be classified as either due to genetic mutations, also called the congenital LQTS, or as acquired LQTS where cardiac ion channel function is influenced by extrinsic factors. Patients with a prolonged QTc interval are considered at risk of developing the dreaded torsade de pointes (twisting of the points, TdP) ventricular arrhythmia. In many respects the frenetic up and down, twisting-around motion of the waveform is the electrophysiological equivalent of the “twist” dance craze popularized 6 decades ago. Unfortunately, the outcome of the cardiac twist is considerably more somber than the popular dance as it degenerates into ventricular fibrillation and potentially sudden cardiac death about 20% of the time.6 As such, much attention is paid to monitoring the QTc interval, particularly when using medications with potential QT prolonging properties. This can significantly affect clinical decisions since certain hepatic pathologies and/or treatments can further impact the QT interval and may reduce pharmacological treatment options in cirrhotic patients with LQTS.

Despite the mountain of available literature, several key questions remain unsettled. The purpose of this review is to discuss the pathogenic mechanisms and translational significance of prolonged QT intervals in cirrhosis from the dual viewpoints of cardiac electrophysiology and hepatology. The literature search strategy of this narrative review was by selective PubMed searches of papers over the past 3 decades under the search terms “QT interval,” “QT prolongation,” “prolonged QT,” “ventricular repolarization,” and “cirrhosis.” Papers on repolarization and LQTS in the noncirrhotic cardiovascular population were selected based on personal knowledge of the literature by the three cardiac electrophysiologist authors.

**THE QT INTERVAL**

The QT interval on the ECG represents the total sum of ventricular myocardium action potentials and is defined as the time interval between the start of depolarization and the end of repolarization of the ventricular myocardium (Fig. 1).7

To understand the pathophysiology of QT prolongation, a basic knowledge of the ventricular action potential and its most dominant ion channels is crucial (Fig. 1). The action potential starts with a rapid depolarization, phase 0, mediated by voltage gated sodium channels (\(I_{Na}\)). In phase 1, the voltage gated sodium channels close and a transient outward current (\(I_{to}\)) corresponding to the end of the T-wave on the ECG. Phase 2: plateau phase by an equilibrium between the inward calcium current by L-type calcium channels and an outward potassium current \(I_{Ks}\) and \(I_{Kur}\). Phase 3: repolarization by closure of the L-type calcium channels, and outward potassium currents \(I_{Ks}\) and \(I_{Kur}\) corresponding to the end of the T-wave on the ECG. Phase 4: a slow depolarization occurs if the current reaches the threshold, which initiates the next depolarization.
curate and reproducible method is the “tangent method,” although other methods are available for more complex T waves. In the tangent method, the end of the T-wave is defined as the intersection of the tangent of the rapid downslope of the T-wave and the iso-electric T-P segment.

In general, the longest measured QT interval on a 12 lead ECG is used, as some leads may have isoelectric portions of the QT interval which may be erroneously left out of the QT measurement. Automated analysis programs use slightly different methods. For example, the common GE Marquette 12SL™ ECG Analysis Program measures the QT interval from the earliest detection of depolarization in any lead to the latest detection of repolarization in any lead. However, these algorithms have proven to be highly reliable and reproducible, although their precision remains dependent on the overall ECG quality.

### THE CORRECTED QT (QTc) INTERVAL

With increasing heart rates, the time between cardiac cycles shortens. As the duration of ventricular depolarization, measured as the QRS complex duration on the ECG, remains unchanged, ventricular repolarization has to shorten. Therefore, the uncorrected QT interval is highly dependent on heart rate. In order to compare QT intervals at different times and at different heart rates, the QT interval is corrected for heart rate with mathematical formulas and the QTc interval represents the QT interval at 60 beats per minute. In 1920, Bazett presented the first QT correction formula (QTc=QT/RR^1/2), which until today is still the most widely used formula in clinical practice. A major criticism of the Bazett formula is its overcorrection at higher and lower heart rates. As the goal of QT interval correction is to remove its dependency of heart rate, studies that present QTc intervals corrected with Bazett formula and do not adjust for heart rate render inaccurate results that cannot be independently related to the QTc interval. In the same year, Fridericia already presented a more optimal method (QTc=QT/RR^1/3), that has more recently been shown to provide most accurate QT correction in patients with normal and abnormal heart rates when compared with other formulas. Fridericia's formula also outperformed other formulas in atrial fibrillation and improved risk prediction for all-cause mortality. A difficult population for QTc correction and interpretation are patients with ventricular conduction defects, defined as a QRS duration >120 ms. Over time, multiple adjustments or tricks have been suggested to correct the QT interval in these patients, however the Rautaharju formula [QT–0.155(RR–1)–0.93(QRS–0.139)+k with k=−0.022s for men and k=−0.034s for women] have been shown to correct for QRS duration, as well generating QTc values interpretable with common cutoffs for normal values and has been shown to predict mortality as well. In the acute setting at an emergency department, the use of appropriate QT correction formulas has shown to reduce the number of patients considered to have a prolonged QTc by 65%. In patients with liver disease, the Fridericia formula has recently been shown to be superior over other formulas and its use is therefore recommended in patients with cirrhosis.

Identifying significant QTc prolongation starts with defining normal values (Table 1). Overall, a QTc interval >450 ms in male and >470 ms in females are considered prolonged. More than a single QTc measurement, the change of the QTc interval in time is relevant, for example after starting a new potentially QT prolonging drug. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has provided recommendations on the design, conduct, analysis, and interpretation of thorough QT/QTc studies, which intend to determine whether a drug has a threshold pharmacologic effect on cardiac repolarization. In these ICH E14 guidelines a significant QTc prolongation is defined as an increase in QTc >60 ms or an absolute QTc interval >500 ms. The cutoff of >500 ms originates from observational studies in patients with congenital LQTS and a QTc >500 ms was associated with life-threatening cardiac events and TdP.

### LONG QT SYNDROME

The LQTS is a heterogeneous group of disorders which cause prolongation of cardiomyocyte repolarization. The LQTS in noncirrhotic populations can be divided in two forms, as described above. The congenital LQTS comprises patients with hereditary genetic mutations affecting cardiac ion channels. Thus far, mutations in 16 different genes causing congenital LQTS have been identified. Despite this, 15% to 20% of congenital LQTS patients will not have a detectable gene mutation and may represent yet undiscovered LQTS genotypes or de novo mutations. The acquired LQTS is predominantly caused by extrinsic factors which

---

**Table 1. Normal Values for QTc Intervals by Sex**

| QTc Interval | Males     | Females    |
|-------------|-----------|------------|
| Normal, ms  | <430      | <450       |
| Borderline, ms | 430–450  | 450–470    |
| Prolonged, ms | >450      | >470       |

QTc, corrected QT.
influence cardiac repolarization. The pharmacological blockade of cardiac ion channels, either through on target (e.g., sotalol) or off target effects (e.g., cisapride) of a wide range of drug therapies, is by far the most common cause of acquired LQTS. Most drugs that cause a LQTS do so through blockade of the delayed rectifier current potassium channel (I_Kr), which is coded by the human ether-a-go-go gene (hERG). Due to its promiscuous pore structure, a variety of drug moieties can bind to the hERG-channel and block its inner pore thereby reducing I_Kr currents resulting in slowing of phase 3 repolarization. A complete list of drugs associated with a risk of QTc prolongation can be found at www.CredibleMeds.org. They present 4 lists of drugs: 1: drugs with a known risk for TdP, 2: drugs with a possible risk for TdP, 3: drugs with a conditional risk for TdP, and 4: drugs to be avoided by patients with congenital LQTS) that are being updated continuously based on available evidence. Further, inadvertent combination of these at-risk drugs may synergistically compound QT prolongation either through direct effects on cardiac ion channels or through induction or suppression of drug metabolism pathways (often cytochrome P450).

Also known to cause QT prolongation are bradycardia, especially acutely following cardioversion of atrial fibrillation, female sex, electrolyte abnormalities such as hypokalemia and hypomagnesemia; as well as structural heart disease such as hypertrophy, ischemia, and heart failure. There may also be a potential contribution of genetic abnormalities in acquired LQTS after all. It is widely known that there is variable penetrance of the congenital LQTS with many phenotype negative, genotype positive patients. An estimated 10% to 15% of silent congenital LQTS patients will be unmasked through consumption of a QT prolonging drug and may initially be considered as acquired LQTS. In a recent study, about one-third of acquired LQTS patients actually carried a known congenital LQTS mutation and both common and rare genetic polymorphisms that could induce QTc prolongation when cumulated were described.

In clinical practice the congenital and acquired LQTS represent opposite ends of a wide spectrum rather than 2 distinct disease entities. The overarching principle is that manifest LQTS is a multi-hit disease process. Typically, the combination of several risk factors is required to erode a patient’s “repolarization reserve,” to significantly prolong the QTc interval and establish a clinically relevant LQTS. It is this complexity of LQTS, and its heterogeneity in presentation, that makes it hard to predict which patient will develop an acquired LQTS and should be considered at risk for TdP. Many risk scores to predict significant QTc prolongation have been developed, however only a few include liver disease. The long-term association between a prolonged QTc and mortality has been studied extensively. In the Framingham Heart Study a prolonged QTc was associated with a 84% increased risk of all-cause mortality over a mean follow-up of 27 years, but there was no significant association specifically with sudden cardiac death. In a large primary care population of 173 529 patients aged between 50 and 90 years with a mean follow-up of 6 years, a prolonged QTc was an independent predictor of all-cause mortality, cardiovascular mortality and non-cardiovascular mortality in both men (hazard ratio 2.53, 4.08, and 2.14, respectively) and women (hazard ratio 1.52, 2.09, and 1.38, respectively). These findings were confirmed in an in-hospital population. The short-term predictive value for a prolonged QTc at the emergency department to predict in-hospital mortality was limited, whereas a severely prolonged QTc >500 ms was associated with in-hospital cardiovascular events.

**TORSADE DE POINTES**

The most severe complication of LQTS is the idiosyncratic polymorphic ventricular tachycardia TdP (Fig. 2). TdP is often self-limiting and reverts back to sinus rhythm, but can also deteriorate into ventricular fibrillation and lead to sudden cardiac death. The term TdP was introduced by Dessertenne in 1966 due to the typical pattern of twisting points. The electrocardiographic features of TdP are first, a twisting change in the morphology and amplitude of the ventricular activity around the isoelectric baseline. However, since each ECG lead presents data from its corresponding vector through the heart, this may not be seen in all leads. Second, the initiation of TdP is typically

![Continuous electrocardiogram monitoring strip of a patient with torsade de pointes (TdP) ventricular tachycardia. Typical electrocardiographic presentation of TdP ventricular tachycardia. 1: Short-coupled premature atrial beat. 2: Compensatory pause after the premature atrial beat. 3: Short-coupled premature ventricular beat resulting in a “short-long-short” (1-2-3) sequence initiating TdP. 4: Warm-up phenomenon with slightly longer RR intervals initially. 5: Typical twisting morphology and amplitude of the ventricular activity around the isoelectric baseline during TdP.](image-url)
preceded by a “short-long-short” sequence with a longer than usual pause and then a short-coupled premature ventricular beat on the next T-wave, which is the vulnerable phase of the myocardium. Third, TdP illustrates a warm-up phenomenon in the first beats of the arrhythmia with longer RR-intervals before the typical pattern of TdP starts. The self-limiting properties imply that the true incidence of TdP is unknown, but only estimated. In hospitalized patients the incidence of TdP in patients with acquired LQTS was estimated at 0.016% per year based on data collected over a 3-year period in a tertiary care hospital.47

The pathophysiology and arrhythmogenesis of TdP starts with a prolonged repolarization of the ventricular action potentials due to a decreased repolarizing potassium current, usually due to I Kr, blockade (Fig. 3).48,49 On a cellular level, this may lead to "early afterdepolarizations," which occur when the membrane potential remains sufficiently high to re-open voltage-gated L-type calcium channels after they are no longer refractory. If this early afterdepolarization reaches the threshold to initiate a ventricular contraction, then this is called "triggered activity" which causes the short-coupled premature ventricular beat on the T-wave that can initiate TdP.

There are regional differences in ventricular action potential duration throughout the myocardium. Mid-myocardial M-cells show a proportional higher increase in action potential duration with I Kr blockade compared to epicardial and endocardial cells. This results in a transmural dispersion of ventricular repolarization as cells with a slightly prolonged action potential are next to cells with a much longer action potential duration. In contrast to the normal pattern of depolarization and repolarization of the ventricular myocardium, this ventricular repolarization gradient means that depolarized cells are very close to cells that are no longer refractory, separated by a layer of cells with a very long refractory period. When this transmural dispersion reaches an arrhythmic threshold and coincides with triggered activity, this may result in an intra-mural reentrant circuit causing TdP.

As can be deduced from the above, the likelihood of developing TdP depends on coincidences. As a result, the ability to predict who will develop TdP is fairly limited. On a population level, due to the many factors that influence the QTc interval (e.g., obesity, diabetes, cardiomyopathies, and neurological disorders), a prolonged QTc interval may reflect a generic, long-term risk factor, unless acute changes in the QTc interval are present which may serve as a short-term risk factor.17 Several of these acute ECG features associated with development of TdP have been described, such as short-term QT variability,50 T-wave alternans,51 T-peak to T-end time,52 and T-wave notching.53 As most of these features are associated with imminent TdP, within minutes or hours, their utility for guidance of long-term therapy and risk reduction is limited.

**ACQUIRED LQTS IN CIRRHOSIS**

The wide range of QT prolongation in cirrhosis that is reported between 30% and 70% does not allow an exact estimate of the prevalence of acquired LQTS in these patients.2,3 There are several factors underlying the significant discrepancies in the literature. First, the vast majority of studies are retrospective with the inherent limitations of this design. Second, cirrhosis or chronic liver disease has many etiologies and liver dysfunction runs the gamut from mild dysfunction to end-stage liver failure with an expected untransplanted survival measured in months. This implies significant heterogeneity in study populations due to selection bias. Third, most studies report QTc intervals with the Bazett formula and therefore present overestimated QTc values. Lastly, a prolonged QTc was not defined consistently, and endpoints differed between studies. It is therefore not surprising that there are widespread discrepancies in the literature. As a result, there is an under-ap-
preciation of the magnitude of the prevalence and severity of this disease in the cirrhosis population which can affect clinical decision-making since certain hepatic pathologies and/or treatments can further impact on cardiac repolarization.

In the setting of cirrhosis, the presence of LQTS can present as a clinical conundrum with a variety of non-hepatic issues to consider. This is supported by the observation that in patients with a prolonged QTc prior to liver transplantation, the QTc interval normalized in over half of the patients after transplant.\textsuperscript{54-56} Hence, cirrhosis has an independent effect associated with QT prolongation, but these may at least be partially reversible. Besides known extrinsic causes, such as off-target I\textsubscript{Ks} blockade of drugs, induction or suppression of cytochrome P450 drug metabolism pathways, and electrolyte abnormalities exacerbated by loop diuretics, the mechanisms underlying QT prolongation in cirrhosis are poorly understood. There are a variety of proposed mechanisms, but there remains a paucity of published literature which adequately examines these mechanisms in a comprehensive translational manner from bench to bedside.

One such proposed mechanism is the accumulation of hepatic metabolites such as bile acid salts.\textsuperscript{57,58} There is evidence that cardiac myocytes express nuclear bile acid receptors: farnesoid-X receptor\textsuperscript{59} and Takeda G-protein receptor 5.\textsuperscript{60,61} The underlying cellular pathophysiology was studied by Ward\textsuperscript{et al.}\textsuperscript{62} in bile duct ligated-cirrhotic rats and they found a decrease in expression of I\textsubscript{Ks} and I\textsubscript{CaL} resulting in prolonged action potential duration. In contrast, patch clamp experiments of ventricular cardiomyocytes perfused with bile acids demonstrated a decrease in inward Ca\textsuperscript{2+} currents and an increase in outward K\textsuperscript{+} currents, the net result being an overall shortening of the QTc.\textsuperscript{63} However, the latter was performed in otherwise healthy rat myocardium, whereas the former study was performed after bile duct ligation. Moreover, multivariate analysis of serum bilirubin, serum cholic acid and serum ursodeoxycholic acid failed to show a significant correlation with QTc prolongation in human cirrhosis patients.\textsuperscript{5} Further, studies have observed QT prolongation in patients with portal hypertension when compared to healthy controls and patients with normal portal pressures.\textsuperscript{64} This QT prolongation was also observed in patients with noncirrhotic portal hypertension. Portosystemic shunting results in dumping cardiotoxic substances, bile salts, endotoxin and cytokines into the systemic circulation, which may have a detrimental effect on cardiomyocytes. The insertion of a transjugular intrahepatic portosystemic shunt was also associated with a sustained increase in QTc interval.\textsuperscript{65}

Another possible mechanism is autonomic nervous system dysfunction which is a common phenomenon and is associated with a poor prognosis in cirrhosis patients.\textsuperscript{66} Additionally, autonomic imbalance has been shown to affect QT prolongation.\textsuperscript{67,68} Therefore, autonomic dysfunction in the setting of cirrhosis could potentially produce manifest LQTS. In support of this, Bernardi\textsuperscript{et al.}\textsuperscript{5} demonstrated a positive association between QT interval and plasma nor-epinephrine in cirrhosis patients which suggests an adverse response to increased sympathetic nervous system tone. Moreover, unpublished data from the same group showed use of beta-blockers decreased the QTc interval for the same cirrhosis population.\textsuperscript{69} In contrast, two studies were unable to show an association between cardiac autonomic neuropathy and LQTS in the setting of cirrhosis.\textsuperscript{70,71} The extent to which autonomic dysfunction contributes to LQTS in the setting of cirrhosis is not yet fully understood.

Classically, female sex but specifically estrogen, is known to be a risk factor for acquired LQTS. The QT interval of normal males and females diverge after puberty,\textsuperscript{72} and in females the QT interval cycles in synchrony with the menstrual cycle, averaging 10 ms shorter in the luteal phase (low estrogen–high progesterone) compared to the follicular phase (high estrogen–low progesterone).\textsuperscript{73} Moreover, studies have also demonstrated the QT shortening effects of testosterone and progesterone.\textsuperscript{74,75} Similarly, hypoandrogenism and hyperestrogenism is observed in cirrhosis due to increased peripheral conversion of androgen sex hormones to estrogen.\textsuperscript{76} Interestingly, in contrast to the normal population, there is no sex difference in QT prolongation in LQTS cirrhosis patients, suggesting that these secondary peripheral conversion mechanisms have suppressed the normal gonadal hormone influence on QT interval.\textsuperscript{5,66,77}

The presence of cardiomyopathy and heart failure itself are well-known risk factors for acquired LQTS.\textsuperscript{34,36,37,78} The levels of brain natriuretic peptide and pro-brain natriuretic peptide, cardiac peptides reflecting ventricular dysfunction, are increased in cirrhotic patients and correlate with the severity of disease and the QT interval.\textsuperscript{79} Several conditions such as excessive alcohol consumption, hemochromatosis and cirrhotic cardiomyopathy may induce both cirrhotic and cardiomyopathic disease processes. Bernardi\textsuperscript{et al.}\textsuperscript{5} demonstrated that there was no difference in QT interval between alcoholic cirrhosis and non-alcoholic cirrhosis, suggesting that the cirrhosis itself is the driving factor in QT prolongation and not a common underlying pathophysiological mechanism which independently causes both cirrhosis and LQTS. The pathophysiology of cirrhotic cardiomyopathy itself is yet to be fully elucidated. Biochemical mechanisms such as lipopolysaccharide,\textsuperscript{80} tumor necrosis factor-\textit{α},\textsuperscript{81} endocannabinoids\textsuperscript{82} and dysregulation...
of β-adrenergic receptors contribute to the pathogenesis of cirrhotic cardiomyopathy. However, what role these mechanisms play in the genesis of repolarization abnormalities in cirrhosis remains unclear. Indeed, a recent study by Koshy et al. demonstrated no correlation between LQTS and either the 2005 World Congress of Gastroenterology or 2020 Cirrhotic Cardiomyopathy Consortium diagnostic criteria for cirrhotic cardiomyopathy, suggesting that LQTS and cirrhotic cardiomyopathy are separate and unrelated phenomena. However, this conclusion is controversial, with some believing that the presence of cirrhotic cardiomyopathy may contribute to the manifestation of LQTS, and also increase the risk of fatal arrhythmias.

**RISK OF LQTS IN CIRRHOSIS**

Despite the lack of understanding about the underlying mechanisms of cirrhosis related acquired LQTS, the clinical significance of cardiac-hepatic interactions cannot be overstated. Specifically, the key question is whether acquired LQTS in cirrhosis is pro-arrhythmic, similar to the noncirrhotic patients with LQTS. If so, a failure to recognize these interactions could result in severe arrhythmic consequences for the patient.

The literature on the predictive value of a prolonged QTc interval in patients with cirrhosis is unclear due to heterogeneous study designs with different exclusion criteria, different levels of characterization of the study population, use of different correction formulas and lack of time-to-event analysis. Multiple studies reported on the association between the QTc interval and mortality in patients with cirrhosis. Kazankov et al. and Zhao et al. reported no predictive value for a prolonged QTc interval in their prediction models, whereas Kim et al. reported a 69% higher mortality rate in patients with a prolonged QTc interval. Further, Biselli et al. reported an increased short-term mortality within 6 weeks after admission of patients with cirrhosis for gastrointestinal bleeding, on top of the Model for End-Stage Liver Disease-sodium (MELD-Na) score. In multiple studies, the QTc interval was significantly associated with measures of disease severity, such as liver function tests and the Child-Pugh score.

Data after liver transplantation are again conflicting. Ko et al. reported changes in QTc intervals after transplant and reported QTc shortening in 73% of patients. They did not observe an association between the QTc interval after transplantation and mortality during follow-up. Similar results were presented before in smaller populations. Lee et al. reported no significant difference in outcome when using an ECG prior to the transplant, but a 78% higher mortality if QTc prolongation was present 1 month after liver transplant.

**MANAGEMENT OF LQTS IN CIRRHOSIS**

Based on the available literature, it is safe to state that there is a significant association between the QTc interval and the severity of liver disease. There may also be a significant association with mortality. When treating cirrhosis patients there are specific clinical scenarios which may worsen QT prolongation and therefore increase the risk of TdP. Acute awareness of these situations may help to avoid calamity, but at a cost of limiting treatment options for a patient. Table 2 presents relevant risk factors which should be assessed and (and prevented when possible) in case of acquired LQTS.

First, each cirrhosis patient should have a good quality 12-lead ECG available to assess a baseline QTc interval. The presence of a prolonged QTc interval at baseline, as a measure of reduced repolarization reserve, may be a strong predictor to develop acquired LQTS in the future. This could be combined with a thorough cardiovascular examination, including familial history and history of previous arrhythmias. If a patient presents with significant QTc

| Table 2. Risk Factors to Assess in the Presence/Prevention of Acquired Long QT Syndrome |
|---|---|
| **Risk factor** | **Mitigation strategy** |
| Previous QTc prolongation | Check prior ECGs to establish a baseline QTc interval |
| Prior cardiovascular history | Thorough assessment of cardiovascular history |
| Acute illness and infection | Physical examination and treat infections |
| Known QT prolonging drugs | Check lists 1 and 2 on CredibleMeds.org |
| Conditional QT prolonging drugs | Check list 3 on CredibleMeds.org |
| Electrolyte abnormalities | Check and correct potassium, magnesium and calcium levels |
| Thyroid disturbances | Check thyroid function and replacement therapies |
| Bradycardia-arrhythmias | Assess for pacing indication and anti-arrhythmic therapy |
| Cardiomyopathy | Diagnose and treat according to most recent guidelines |

QTc, corrected QT; ECG, electrocardiogram.
prolongation, this patient should be assessed for acute illnesses and infections, as these may further impact the outcome. Patients presenting with sepsis, bleeding or liver failure, should be closely monitored for electrophysiological abnormalities, including continuous cardiac monitoring. Additional investigations may be needed, including biochemistry with electrolytes, and thyroid indices.

Although many clinicians caring for severely ill cirrhotic patients have almost never observed TdP in this population and thus believe that it may be a rare arrhythmia even in those with prolonged QTc, this might be an inaccurate opinion. The majority of cirrhotic patients dying of end stage liver failure, or acute-on-chronic liver failure precipitated by conditions such as sepsis, bleeding, or other insults, usually do not undergo continuous ECG monitoring. It is therefore quite possible that the agonal event in many such patients is a significant arrhythmia, and a death ascribed to "liver failure" may actually have been a sudden cardiac death.

By far the most common cause of acquired LQTS is a drug-drug interaction. Some classes of medication with well-known I_{Ks} affinity are frequently used in cirrhosis patients, including fluoroquinolone antibiotics, antidepressants, anti-emetics and analgesics. These can be found at www.CredibleMeds.org in lists 1 and 2. As described above, drug-drug interactions are not necessarily restricted to off-target I_{Ks} blockade, but could also result from suppressed cytochrome P450 enzyme activity due to hepatic impairment. Carbamazepine, for example, has modest hERG affinity in the micromolar range, but severe QT prolongation can occur when combined with a macrolide antibiotic such as erythromycin, due to CYP3A4 inhibition leading to significant increase in bioavailability of carbamazepine. Activity of CYP1A2, 2C19 and 3A are more sensitive to cirrhosis, whereas 2D6, 2C9 and 2E1 seem less affected. When no drugs from www.CredibleMeds.org lists 1 or 2 can be identified, one can often identify drugs that exacerbate other LQTS risk factor (www.CredibleMeds.org list 3). Examples include loop diuretics and proton pump inhibitors. Loop diuretics are often used in the treatment of ascites, but if unmonitored these can lead to massive urinary losses of potassium and magnesium and resultant hypokalemia and hypomagnesemia. The use of proton pump inhibitors is associated with hypomagnesemia and have shown to be related to the risk of TdP. A practical approach to mitigating risk associated with drug-induced LQTS to is refer to the aforementioned lists of QT prolonging drugs whenever commencing a new drug therapy on a LQTS patient. In many cases, non-QT prolonging alternatives are available, without losing too much efficacy, for example antidepressants. Importantly, many of the QT prolonging effects are idiosyncratic to the specific molecules, and not due to a “class effect”.

Bradycardia, either due to sick sinus syndrome, atrioventricular block or cirrhosis-related chronotropic incompetence, can result in an excessive increase of QT prolongation, and put the patient at risk of the "short-long short" sequences which typically initiate TdP. In severe cases, a cardiac pacing strategy programmed with a sufficiently fast lower rate may be recommended. In many cases, the cardiac substrate for arrhythmia may be more complex. Heart failure in itself is a risk factor for TdP as well as other ventricular arrhythmias. Cirrhotic cardiomyopathy can be both a risk factor for cirrhotic LQTS, as well as an exacerbating factor cirrhotic LQTS. Therefore, a thorough cardiac evaluation, including a plasma brain natriuretic peptide level and a transthoracic echocardiogram, is indicated in case of high clinical suspicion, as these cardiac conditions would require dedicated heart failure and arrhythmia management. Beta-blockers are protective against arrhythmias in the LQTS-cirrhosis population most likely due to their sympathomimetic effect.

In patients with cirrhosis, multiple hits and cardiac-hepatic interactions are often required to sufficiently erode the repolarization reserve before manifest acquired LQTS and TdP can occur. Physicians should have a high index of clinical suspicion for acquired LQTS when treating cirrhosis patients. Whilst some risk factors (e.g., medical conditions, cardiovascular conditions and genetic predisposition) are unavoidable, the patients’ risk of developing acquired LQTS can be mitigated by avoiding drug interactions, electrolyte imbalances and ECG monitoring. In some cases, a joint effort by cardiologists and hepatologists may be needed, and this may significantly improve a patient’s clinical course and outcome.

**CONCLUSION**

Cirrhosis-related LQTS is common and can significantly affect a patient’s therapeutic options as well as long-term prognosis. Some efforts have already been undertaken to understand the etiology of this disease, but the true mechanistic pathophysiology remains elusive. Areas of interest may include metabolic, autonomic or hormonal imbalances, cirrhotic heart failure and/or genetic predisposition.

In practice, a high index of clinical suspicion is required to avoid drug interactions and to mitigate other risk factors in an effort to reduce the risk of QT prolongation and fatal arrhythmias. When severely ill cirrhotic patients, whether pre- or post-transplant, are admitted for complications such as sepsis, bleeding or liver failure, we recommend that
they be closely monitored for electrophysiological abnormalities. In those with a prolonged QTc continuous ECG monitoring should be strongly considered.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

B.V. is supported by a research grant of the Frans Van de Werf Fund for Clinical Cardiovascular Research (Leuven, Belgium). S.R.R. receives research support from the Canadian Institutes of Health Research (grant MOP142426). This work was supported in part by the National Center for Advancing Translational Sciences (NCATS) Award UL1 TR000445.

ORCID

William Lee https://orcid.org/0000-0001-5014-0851
Bert Vandenberk https://orcid.org/0000-0001-8296-920X
Satish R. Raj https://orcid.org/0000-0002-5890-3785
Samuel S. Lee https://orcid.org/0000-0003-4431-272X

REFERENCES

1. Mann K, Chappelle D. Let's Twist Again. Philadelphia: Cam-emo-Parkway Records, 1961.
2. Chahal D, Liu H, Shamaturu C, Sidhu H, Lee SS, Marquez V. Review article: comprehensive analysis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther 2021;53:985-998.
3. Yoon KT, Liu H, Lee SS. Cirrhotic cardiomyopathy. Curr Gastroenterol Rep 2020;22:45.
4. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
5. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
6. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010;121:1047-1060.
7. Garson A Jr. How to measure the QT interval: what is normal? Am J Cardiol 1993;72:14B-16B.
8. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol 2006;17:333-336.
9. Panicker GK, Karnad DR, Natekar M, Kothari S, Narula D, Lokhandwala Y. Intra- and interreader variability in QT interval measurement by tangent and threshold methods in a central electrocardiogram laboratory. J Electrocardiol 2009;42:348-352.
10. Hnatkova K, Gang Y, Batchvarov VN, Malik M. Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol 2006;29:1277-1284.
11. Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 2016;5:e003264.
12. Bazett HC. An analysis of the time relations of electrocardio-grams. Heart 1920;7:353-370.
13. Malik M, Färbohm P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87:220-228.
14. Vandenberk B, Vandael E, Robyns T, et al. QT correction across the heart rate spectrum, in atrial fibrillation and ventricular conduction defects. Pacing Clin Electrophysiol 2018;41:1101-1108.
15. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkrankern. Acta Medica Scandinavica 1920;53:469-486.
16. Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017-1021.
17. Vandenberk B, Siau C, Vandael E, et al. A prolonged QTc-interval at the emergency department: should we always be prepared for the worst? J Cardiovasc Electrophysiol 2019;30:2041-2050.
18. Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevi-sani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol 2007;18:77-82.
19. Głóvczyńska R, Galas M, Oldakowska-Jedynak U, et al. Pretransplant QT interval: the relationship with severity and etiology of liver disease and prognostic value after liver transplantation. Ann Transplant 2018;23:622-630.
20. Kazankov K, Jensen HK, Watson H, Vilstrup H, Bernardi M, Jepsen P. QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascites. Scand J Gastroenterol 2019;54:1376-1378.
21. U.S. Department of Health and Human Services; Food and Drug Administration Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Geneva: ICH, 2005.
22. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007;49:329-337.
23. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-1874.
24. van Noord C, Eijgelsheim M, Stricker BH. Drug- and nondrug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70:16-23.
25. Giudicessi JR, Wilde AAM, Ackerman MJ. The genetic architecture of long QT syndrome: a critical reappraisal. Trends Cardiovasc Med 2018;28:453-464.
26. Wallace E, Howard L, Liu M, et al. Long QT syndrome: genetics and future perspective. Pediatr Cardiol 2019;40:1419-1430.
27. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760-781.
28. Vandenberg JJ, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 2012;92:1393-1478.
29. Woosley RL, Heise CW, Gallo T, Tate J, Woosley D and Romero KA. QTdrugs List [Internet]. Oro Valley: AZCERT, Inc.; c2021 [cited 2021 Sep 1]. Available from: www.Crediblemeds.org.
30. Dessertenne F, Fabiato A, Coumel P. A new chapter of electrocardiography: the progressive variations in the amplitude of the electrocardiogram. 1966. Cardiovasc Drugs Ther 1991;5:171-190.
31. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-1093.
32. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
33. Roden DM, Iansmith DH. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med 1987;82:18-23.
34. Tomaselli GF, Marbán E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-283.
35. Halkin A, Roth A, Lurie I, Fish R, Belhassen B, Viskin S. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J Am Coll Cardiol 2001;38:1168-1174.
36. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
37. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 2017;39:16-25.
38. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761-1767.
39. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004;82:182-188.
40. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 2016;37:1456-1464.
41. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
42. Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 2017;39:424-432.
43. Vandael E, Vandenberk B, Vandenberghe J, Van den Bosch B, Willems R, Foulon V. A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol 2018;84:2824-2835.
44. Noseworthy PA, Peloso GM, Hwang SJ, et al. QT interval and long-term mortality risk in the Framingham Heart Study. Ann Noninvasive Electrocardiol 2012;17:340-348.
45. Nielsen JB, Graff C, Rasmussen PV, et al. Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population. Eur Heart J 2014;35:1335-1344.
46. Dessertenne F. Ventricular tachycardia with 2 variable opposing loci. Arch Mal Coeur Vaiss 1966;59:263-272.
47. Vandael E, Vandenberk B, Vandenberghe J, Pincé H, Willems R, Foulon V. Incidence of torsades de pointes in a tertiary hospital population. Int J Cardiol 2017;243:511-515.
48. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-1372.
49. Zareba W. Drug induced QT prolongation. Cardiol J 2007;14:523-533.
50. Hinterseer M, Thomsen MB, Beckmann BM, et al. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. Eur Heart J 2008;29:185-190.
51. Takasugi N, Goto H, Takasugi M, et al. Prevalence of microvolt T-wave alternans in patients with long QT syndrome and its association with torsade de pointes. Circ Arrhythm Electrophysiol 2016;9:e003206.
52. Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003;105:671-676.
53. Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsades de pointes during acquired
bradyarrhythmias. J Am Coll Cardiol 2007;49:320-328.
54. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003;23:243-248.
55. Zamirian M, Tavassoli M, Aghasadeghi K. Corrected QT interval and QT dispersion in cirrhotic patients before and after liver transplantation. Arch Iran Med 2012;15:375-377.
56. Adigun AQ, Pinto AG, Flockhart DA, et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005;95:691-694.
57. Desai MS, Mathur B, Eblimit Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology 2017;65:189-201.
58. Desai MS, Penny DJ. Bile acids induce arrhythmias: old metabolite, new tricks. Heart 2013;99:1629-1630.
59. Pu J, Yuan A, Shan P, et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury. Eur Heart J 2013;34:1834-1845.
60. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435-9440.
61. Eblimit Z, Thevananther S, Karpen SJ, et al. TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. Cardiovasc Ther 2018;36:e12462.
62. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273(2 Pt 1):G537-G544.
63. Binah O, Rubinstein I, Bomzon A, Better OS. Effects of bile acids on ventricular muscle contraction and electrophysiological properties: studies in rat papillary muscle and isolated ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1987;335:160-165.
64. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005;43:637-644.
65. Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461-467.
66. Fleckenstein JF, Frank Sm, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology 1996;23:471-475.
67. Oka H, Mochio S, Sato K, Isogai Y. Correlation of altered Q-T interval and sympathetic nervous system dysfunction in diabetic autonomic neuropathy. Eur Neurol 1994;34:23-29.
68. Diedrich A, Jordan J, Shannon JR, Robertson D, Biaggioni I. Modulation of QT interval during autonomic nervous system blockade in humans. Circulation 2002;106:2238-2243.
69. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994-1002.
70. Puthuman A, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol 2001;35:733-738.
71. Tsiokanapis E, Siakavellas S, Tantouloris A, et al. Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity. World J Gastrointest Pathophysiol 2018;9:28-36.
72. Vink AS, Clur SB, Geskus RB, et al. Effect of age and sex on the QTc interval in children and adolescents with type 1 and 2 long-QT syndrome. Circ Arrhythm Electrophysiol 2017;10:e004645.
73. Nakagawa M, Ooie T, Takahashi N, et al. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 2006;29:607-613.
74. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005;112:1701-1710.
75. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation 2007;116:2913-2922.
76. Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 1975;40:1018-1026.
77. Taneru E, Donouio J, Istriotoe A, et al. Q-T interval prolongation in patients with liver cirrhosis. Curr Health Sci J 2018;44:274-279.
78. Törp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmias and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-865.
79. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517.
80. Joseph LC, Reyes MV, Lakkadi KR, et al. PKCδ causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction. Am J Physiol Heart Circ Physiol 2020;318:H778-H786.
bile duct-ligated mice. Clin Sci (Lond) 2014;127:519-526.
83. Lee SS, Marti J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990;12(3 Pt 1):481-485.
84. Koshy AN, Gow PJ, Testro A, et al. Relationship between QT interval prolongation and structural abnormalities in cirrhotic cardiomyopathy: a change in the current paradigm. Am J Transplant 2021;21:2240-2245.
85. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012;6:57-66.
86. Zhao J, Qi X, Hou F, et al. Prevalence, risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis. Am J Med Sci 2016;352:285-295.
87. Kim SM, George B, Alcivar-Franco D, et al. QT prolongation is associated with increased mortality in end stage liver disease. World J Cardiol 2017;9:347-354.
88. Biselli M, Gramenzi A, Lenzi B, et al. Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding. Clin Gastroenterol Hepatol 2019;17:1388-1397.
89. Ko J, Koshy AN, Han HC, et al. Effect of liver transplantation on QT-interval prolongation and impact on mortality. Int J Cardiol 2021;326:158-163.
90. Lee SH, Park M, Park KM, et al. Corrected QT interval on the electrocardiogram after liver transplantation: surrogate marker of poor clinical outcomes? PLoS One 2018;13:e0206463.
91. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-487.
92. Pickham D, Helfenbein E, Shinn JA, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med 2012;40:394-399.
93. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12:363-368.
94. Danielsson BR, Lanskell K, Patmore L, Tomson T. Phenytoin and phenobarbital inhibit human hERG potassium channels. Epilepsy Res 2003;55:147-157.
95. Carranco E, Kareus J, Co S, Peak V, Al-Rajeh S. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol 1985;42:187-188.
96. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab 2004;5:273-282.
97. Chvilicek JP, Hurlbert BJ, Hill GE. Diuretic-induced hypokalaemia inducing torsades de pointes. Can J Anaesth 1995;42:1137-1139.
98. Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front Pharmacol 2018;9:363.
99. Wong F, Girgrah N, Graba J, Alldina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001;49:268-275.
100. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000;11:593-600.
101. Alvarez CK, Cronin E, Baker WL, Kluger J. Heart failure as a substrate and trigger for ventricular tachycardia. J Interv Card Electrophysiol 2019;56:229-247.a
102. Yoon KT, Liu H, Lee SS. β-Blockers in advanced cirrhosis: more friend than enemy. Clin Mol Hepatol 2021;27:425-436.